The World Health Organization (WHO) has called for countries to improve access to two lifesaving Ebola medicines, in its first guidelines on the viral disease, published on Friday.
The recommendation follows review and analysis of clinical trials for the monoclonal antibodies mAb114 (known as Ansuvimab or Ebanga) and REGN-EB3 (Inmazeb), which have demonstrated clear benefits for people who have tested positive for Ebola, which is often fatal.
This includes older persons, pregnant and breastfeeding women, children, and newborns whose mothers were confirmed to have Ebola within the first seven days after birth.
Trial by fire
The clinical trials were conducted during Ebola outbreaks. WHO said the largest trial was carried out in the Democratic Republic of the Congo, demonstrating that the highest level of scientific rigour can be applied even during Ebola outbreaks in difficult contexts.
The UN agency also provided recommendations regarding therapeutics that should not be used as treatments, which include ZMapp and remdesivir.
The new guidance, published simultaneously in English and French, will support healthcare providers caring for Ebola patients as well as policymakers involved in outbreak preparedness and response.
It complements clinical care guidance that outlines the optimized supportive care that Ebola patients should receive – from the relevant tests to administer, to managing pain, nutrition and co-infections, and other approaches that put patients on the best path to recovery.
‘Greater chance of recovering’
“This therapeutic guide is a critical tool to fight Ebola,” said Dr Richard Kojan, co-chair of the expert group selected by WHO to develop the guidelines, and President of ALIMA, The Alliance for International Medical Action.
“From now on, people infected with the Ebola virus will have a greater chance of recovering if they seek care as early as possible. As with other infectious diseases, timeliness is key, and people should not hesitate to consult health workers as quickly as possible to ensure they receive the best care possible.”
Fellow co-chair Dr Robert Fowler from the University of Toronto in Canada noted that Ebola used to be perceived as “a near certain killer,” but advances in care and therapeutics over the past decade have revolutionized treatment of the disease.
“Provision of best supportive medical care to patients, combined with monoclonal antibody treatment – MAb114 or REGN-EB3 – now leads to recovery for the vast majority of people,” he added.
Timely access critical
As access to these treatments remains challenging, especially in poor areas, WHO said they should be available where they are most needed, namely in locations where active Ebola outbreaks are occurring, or where the threat of outbreak is high or very likely.
The UN agency stands ready to support countries, manufacturers and partners to improve access to the two medicines.
“We have seen incredible advances in both the quality and safety of clinical care during Ebola outbreaks,” said Dr Janet Diaz, lead of the clinical management unit in WHO’s Health Emergencies programme.
“Doing the basics well, including early diagnosis, providing optimized supportive care with the evaluation of new therapeutics under clinical trials, has transformed what is possible during Ebola outbreaks. This is what has led to development of a new standard of care for patients. However, timely access to these lifesaving interventions has to be a priority”.
Noncommunicable diseases now ‘top killers globally’
From heart disease to cancer and diabetes, noncommunicable diseases (NCDs) now outnumber infectious diseases as the “top killers globally,” the UN health agency said in a new report, released on Wednesday, with one person under 70 dying every two seconds from an NCD.
The report and new data portal, was launched on the sidelines of the 77th session of the General Assembly, at an event co-organized by the World Health Organization (WHO) together with Bloomberg Philanthropies.
NCDs constitute one of the greatest health and development challenges of this century, according to WHO.
Chief among them are cardiovascular diseases, such as heart disease and stroke; cancer; and diabetes and chronic respiratory diseases – as well as mental health illnesses.
Together they account for nearly three-quarters of deaths in the world, taking 41 million lives every year.
The report, Invisible numbers: The true extent of noncommunicable diseases and what to do about them, highlights NCDs statistics to illustrate the true scale of the threats and risk factors they pose.
It also shows cost-effective and globally applicable interventions that can lower those numbers and save lives and money.
“This report is a reminder of the true scale of the threat posed by NCDs and their risk factors,” said WHO chief Adhanom Ghebreyesus.
Sharing the latest country-specific data, risk factors and policy implementation for 194 countries, the NCD data portal brings the numbers in the report to life.
Moreover, it allows data exploration on cardiovascular diseases, cancer, diabetes and chronic respiratory diseases along with their main drivers and risk factors, which include tobacco, unhealthy diet, harmful use of alcohol and lack of physical activity.
The portal spotlights patterns and trends throughout countries and allows comparison across nations and/or within geographical regions.
To date, only a handful of countries are on track to meet the 2030 Sustainable Development Goal (SDG) target of reducing early deaths from NCDs by a third.
And yet, NCDs are at the heart of sustainable development and their prevention and treatment is a prime opportunity for investment that would have myriad impacts on economic growth, far outweighing the money spent.
“It is a misconception” that they are “diseases of high-income countries”, said Bente Mikkelsen, WHO’s Director of Noncommunicable Diseased, adding that a full 85 per cent of all premature deaths happen in low and middle-income countries.
At a critical juncture for public health, WHO said that the new information offers a chance to address the issue and recommends spending more on prevention.
Investing $18 billion a year across all low and middle-income countries could generate net economic benefits of $2.7 trillion by 2030.
At the event, the WHO chief called on global leaders to take urgent action on NCDs and renewed the two-year appointment of Michael R. Bloomberg as WHO Global Ambassador for Noncommunicable Diseases and Injuries – his third reappointment since 2016.
“As we continue to respond to this pandemic and prepare for the next, we have seen the critical importance of addressing a major risk factor in COVID-19 hospitalizations and deaths – noncommunicable diseases,” said Mr. Bloomberg.
He maintained that they can often be prevented with investment in “proven, cost-effective interventions” and looked forward to continuing to make “life-saving investments in NCD and injury prevention” alongside WHO.
Rare Ebola outbreak declared in Uganda
An outbreak of Ebola virus has been declared in Uganda after a case was confirmed in Mubende district, in the centre of the country.
The UN World Health Organization (WHO) said on Tuesday that a sample taken from a 24-year-old man was identified as the relatively rare Sudan strain.
It is the first time in more than a decade that the Sudan strain has been found in Uganda, which also saw an outbreak of the Zaire strain of Ebola virus in 2019.
The latest outbreak follows six suspicious deaths in Mubende district so far this month. There are also eight suspected cases who are receiving care in a health facility.
Dr Matshidiso Moeti, World Health Organization Regional Director for Africa, said that the UN agency was working closely with Ugandan authorities to investigate the source, and support efforts to control it.
“Uganda is no stranger to effective Ebola control”, she said. “Thanks to its expertise, action has been taken to quickly to detect the virus and we can bank on this knowledge to halt the spread of infections.”
No effective vaccine
Existing vaccines against Ebola have proved effective against the Zaire strain but it is not clear if they will be as successful against the Sudan strain, WHO said in a statement.
Ebola is a severe, often fatal illness affecting humans and other primates. It has six different strains, three of which – Bundibugyo, Sudan and Zaire – have previously caused large outbreaks.
Case fatality rates of the Sudan strain have varied from 41 per cent to 100 per cent in past outbreaks. Early roll-out of supportive treatment has been shown to significantly reduce deaths from Ebola, WHO said.
The agency has dispatched supplies to support the care of patients and is sending a specialized tent that will be used to isolate patients.
While ring vaccination of high-risk people with Ervebo (rVSV-ZEBOV) vaccine has been highly effective in controlling the spread of Ebola in recent outbreaks in DRC and elsewhere, said WHO, this vaccine has only been approved to protect against the Zaire strain.
Another vaccine produced by pharmaceutical company Johnson and Johnson may be effective but has yet to be specifically tested against the Sudan strain.
The end of the COVID-19 pandemic is in sight
As the number of weekly reported deaths from COVID-19 plunged to its lowest since March 2020, the head of the World Health Organization (WHO) said on Wednesday that the end of the pandemic is now in sight.
“We have never been in a better position to end the pandemic”, Tedros Adhanom Ghebreyesus told journalists during his regular weekly press conference.
The UN health agency’s Director-General explained however, that the world is “not there yet”.
Finish line in sight
“A marathon runner does not stop when the finish line comes into view. She runs harder, with all the energy she has left. So must we. We can see the finish line. We’re in a winning position. But now is the worst time to stop running”, he underscored.
He also warned that if the world does not take the opportunity now, there is still a risk of more variants, deaths, disruption, and uncertainty.
“So, let’s seize this opportunity”, he urged, announcing that WHO is releasing six short policy briefs that outline the key actions that all governments must take now to “finish the race”.
The policy briefs are a summary, based on the evidence and experience of the last 32 months, outlining what works best to save lives, protect health systems, and avoid social and economic disruption.
“[They] are an urgent call for governments to take a hard look at their policies and strengthen them for COVID-19 and future pathogens with pandemic potential”, Tedros explained.
The documents, which are available online, include recommendations regarding vaccination of most at-risk groups, continued testing and sequencing of the SARS-CoV-2 virus, and integrating effective treatment for COVID-19 into primary healthcare systems.
They also urge authorities to have plans for future surges, including the securing of supplies, equipment, and extra health workers.
The briefs also contain communications advice, including training health workers to identify and address misinformation, as well as creating high-quality informative materials.
Committed to the future
Tedros underscored that WHO has been working since New Year’s Eve 2019 to fight against the spread of COVID and will continue to do so until the pandemic is “truly over”.
“We can end this pandemic together, but only if all countries, manufacturers, communities and individuals step up and seize this opportunity”, he said.
Dr. Maria Van Kerkhove, WHO’s technical lead on COVID-19, highlighted that the virus is still “ intensely circulating” around the world and that the agency believes that case numbers being reported are an underestimate.
“We expect that there are going to be future waves of infection, potentially at different time points throughout the world caused by different subvariants of Omicron or even different variants of concern”, she said, reiterating her previous warning that the more the virus circulates, the more opportunities it has to mutate.
However, she said, these future waves do not need to translate into “waves or death” because there are now effective tools such as vaccines and antivirals specifically for COVID-19.
Ukraine war-induced crisis affecting women and girls disproportionately
A new UN report reveals how the Ukraine war and its global impacts on food, energy, and finance are affecting...
Ireland: Rights experts call for redress for 50 years of systemic racism in childcare institutions
UN-appointed independent human rights experts on Friday called on Irish authorities to provide adequate redress for victims of racial discrimination and...
UN experts strongly condemn death of Mahsa Amini
UN independent human rights experts on Thursday strongly condemned the death of 22-year-old Mahsa Amini, who died in police custody...
A Virus Yet to Be Eradicated
Much as everything in this world, human memory knows its limits. Increasingly receding into a background of the past, episodes...
Untying the Ukrainian Knot: The Continental Union Project
As the fighting in Ukraine rages on, people continue to die, and infrastructure is being destroyed. This means that the...
Middle Eastern Geopolitics in The Midst of The Russo-Ukrainian War
Russia’s national interests have been harmed by the West’s efforts to obstruct Eurasia’s integration and provoke conflict. Support from the...
The Alliance of Downtrodden Empires
There are many commonalities and differences, to the point of contradiction, in the Russian, Iranian, and Turkish political and economic...
Economy3 days ago
Comparison of the US and Chinese economy
Defense4 days ago
A New Strategic Shifts and A New Strategic Concept of NATO
Central Asia4 days ago
Kyrgyz-Tajik Conflict: Small States Becoming Victim In Games Of The Great Powers
Americas4 days ago
Shaping Tenable Policy on North Korea: A U.S. Security Imperative
World News3 days ago
Real house keys were brought under the eyes of 7,000 business leaders: “The human cost of war”
New Social Compact3 days ago
Anatomy of right-wing populism
South Asia3 days ago
The Taliban and the current Afghanistan
Middle East3 days ago
Creating Building Blocks for Cooperative Security in the Middle East